<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01921985</url>
  </required_header>
  <id_info>
    <org_study_id>190/11</org_study_id>
    <nct_id>NCT01921985</nct_id>
  </id_info>
  <brief_title>Terlipressin Administration in Patients Undergoing Major Liver Resection</brief_title>
  <official_title>Terlipressin Administration in Patients Undergoing Major Liver Resection: a Prospective Randomized Blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates if the administration of terlipressin reduces complications after&#xD;
      major liver surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      Surgery offers the only potential cure in many patients with primary or metastatic liver&#xD;
      cancer. Extending the limits and improving safety of liver resection would allow more&#xD;
      patients to benefit from surgery and to increase their survival. The prerequisite for&#xD;
      successful and safe liver surgery is the optimal regeneration of the remaining hepatic tissue&#xD;
      in order to fulfill the metabolic demands of the patient. Liver regeneration depends on a&#xD;
      correct portal pressure and portal blood flow. In the preliminary results the investigators&#xD;
      show an elevation of portal pressure post partial hepatectomy in mice. Pharmacologic&#xD;
      reduction of such elevated portal pressure using terlipressin, a vasopressin agonist, was&#xD;
      associated with improved liver regeneration.&#xD;
&#xD;
      Objective&#xD;
&#xD;
      Surgery offers the only potential cure in many patients with primary or metastatic liver&#xD;
      cancer. Extending the limits and improving safety of liver resection would allow more&#xD;
      patients to benefit from surgery and to increase their survival. Liver regeneration depends&#xD;
      on a correct portal pressure and portal blood flow. Pharmacologic reduction of elevated&#xD;
      portal pressure using terlipressin, a vasopressin agonist, is potentially associated with&#xD;
      improved liver regeneration. Aim: To perform a prospective randomized trial comparing&#xD;
      terlipressin versus placebo in patients undergoing major hepatic resection.&#xD;
&#xD;
      Methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis revealed that no statistical difference will be identified after inclusion of&#xD;
    the patient cohort as foreseen in the sample size calculation&#xD;
  </why_stopped>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with incident of a composite end point</measure>
    <time_frame>one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with pleural effusion</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with surgical site infection</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with sepsis</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with pneumonia</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with intraabdominal hematoma</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with acute renal failure</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with blood transfusion</measure>
    <time_frame>one month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Liver Resection</condition>
  <condition>Liver Failure</condition>
  <arm_group>
    <arm_group_label>Terlipressin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Terlipressin</intervention_name>
    <description>Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).</description>
    <arm_group_label>Terlipressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).</description>
    <arm_group_label>NaCl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing resection of 3 or more liver segments&#xD;
&#xD;
          -  Minimum age of 18&#xD;
&#xD;
          -  Any gender&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Preoperative renal failure (GFR &lt; 50ml/min)&#xD;
&#xD;
          -  Severe liver dysfunction (Child-Turcotte-Pugh grade C)&#xD;
&#xD;
          -  Hyponatremia (&lt;132mmol/l)&#xD;
&#xD;
          -  Severe aortic regurgitation, severe mitral regurgitation, heart failure&#xD;
&#xD;
          -  Symptomatic coronary heart disease&#xD;
&#xD;
          -  Bradycardic arrhythmia (heart rate &lt; 60/min)&#xD;
&#xD;
          -  Peripheral artery occlusive disease (clinical stadium II-IV)&#xD;
&#xD;
          -  Dilatative arteriopathy, history of subarachnoidal bleeding&#xD;
&#xD;
          -  Decompensated arterial hypertension (Blood pressure &gt;160/100mmHg despite intensive&#xD;
             treatment)&#xD;
&#xD;
          -  Present or suspected acute mesenteric ischemia&#xD;
&#xD;
          -  Septic shock&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guido Beldi, Professor Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dep. of Visceral Surgery, University Hospital Berne</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>August 9, 2013</study_first_submitted>
  <study_first_submitted_qc>August 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2013</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

